Corcept Therapeutics (CORT) Accounts Payables (2010 - 2026)

Corcept Therapeutics has disclosed Accounts Payables across 17 years of filings, most recently posting $33.3 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $33.3 million, up 19.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.3 million (up 19.18% YoY), and the FY2025 annual result was $40.4 million, up 163.03% from the prior year.
• Accounts Payables came in at $33.3 million for Q1 2026 at Corcept Therapeutics, down from $40.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $40.4 million in Q4 2025 to a low of $8.0 million in Q2 2023.
• The 5-year median for Accounts Payables is $16.7 million (2023), against an average of $18.6 million.
• Across the five-year window, Accounts Payables dropped 11.61% in 2024 and soared 163.03% in 2025, its largest moves.
• Corcept Therapeutics' Accounts Payables stood at $12.0 million in 2022, then surged by 45.26% to $17.4 million in 2023, then dropped by 11.61% to $15.4 million in 2024, then soared by 163.03% to $40.4 million in 2025, then declined by 17.65% to $33.3 million in 2026.
• The last three Accounts Payables figures came in at $33.3 million (Q1 2026), $40.4 million (Q4 2025), and $34.4 million (Q3 2025), per Business Quant data.